What’s Ahead for Jounce Therapeutics Inc (NASDAQ:JNCE) After More Shorted Shares?

October 7, 2018 - By Dolores Ford

The stock of Jounce Therapeutics Inc (NASDAQ:JNCE) registered an increase of 0.81% in short interest. JNCE’s total short interest was 3.72M shares in October as published by FINRA. Its up 0.81% from 3.69M shares, reported previously. With 284,700 shares average volume, it will take short sellers 13 days to cover their JNCE’s short positions. The short interest to Jounce Therapeutics Inc’s float is 23.7%.

The stock decreased 1.81% or $0.12 during the last trading session, reaching $6.5. About 197,447 shares traded. Jounce Therapeutics, Inc. (NASDAQ:JNCE) has declined 52.81% since October 7, 2017 and is downtrending. It has underperformed by 68.43% the S&P500.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $212.08 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

More news for Jounce Therapeutics, Inc. (NASDAQ:JNCE) were recently published by: Nasdaq.com, which released: “Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the …” on October 01, 2018. Globenewswire.com‘s article titled: “Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference” and published on September 26, 2018 is yet another important article.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.